1. Home
  2. CIK vs AVXL Comparison

CIK vs AVXL Comparison

Compare CIK & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credit Suisse Asset Management Income Fund Inc.

CIK

Credit Suisse Asset Management Income Fund Inc.

SELL

Current Price

$2.34

Market Cap

127.8M

Sector

Finance

ML Signal

SELL

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$1.11

Market Cap

115.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIK
AVXL
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
127.8M
115.9M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
CIK
AVXL
Price
$2.34
$1.11
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
419.3K
★ 1.1M
Earning Date
01-01-0001
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.26
$1.13
52 Week High
$2.88
$7.60

Technical Indicators

Market Signals
Indicator
CIK
AVXL
Relative Strength Index (RSI) 62.48 32.82
Support Level $2.26 $1.14
Resistance Level $2.40 $1.60
Average True Range (ATR) 0.03 0.10
MACD 0.01 0.03
Stochastic Oscillator 91.67 38.24

Price Performance

Historical Comparison
CIK
AVXL

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. UBS Asset Management serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: